<DOC>
	<DOCNO>NCT00424710</DOCNO>
	<brief_summary>This 12 month study monthly injection ranibizumab subject polypoidal choroidal vasculopathy diagnose fluoresceins/indocyanine green ( FA/ICG ) angiography .</brief_summary>
	<brief_title>Ranibizumab Polypoidal Choroidal Vasculopathy ( PCV )</brief_title>
	<detailed_description>Previous treatment subject allow long appropriate washout period elapse . Patients follow 4M ETDRS vision test well schedule OCT , ICG , FA Fundus Photography .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide inform consent comply study assessment duration one year Age &gt; = 25 year Polypoidal Choroidal Vasculopathy note fluorescein ICG angiography : active leakage , active bleeding recent decrease vision BCVA use ETDRS 20/32 20/400 Any history previous vitrectomy Previous cataract ocular surgery within 2 month day 0 Active intraocular inflammation study eye Active infection conjunctivitis , keratitis , scleritis , endophthalmitis either eye Participation another investigational drug within past 30 day Prior sodium pegaptanib , verteporfin photodynamic therapy , intravitreal steroid , bevacizumab within 30 day study entry Blood pressure &gt; 180/110 ( use antihypertensives allow long hypertension control stable ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>choroidal neovascularization</keyword>
</DOC>